title: Targeting angiogenesis in advanced cervical cancer.
abstract: Patients with advanced stage or recurrent cervical cancer represent a population with limited chemotherapeutic options. More specifically, patients with recurrent disease have a poor salvage rate, with a 5-year survival rate of less than 10%. This year, the first prospective phase III clinical trial exploring the anti-angiogenic agent, bevacizumab, was published, meeting its primary endpoint, with a significant improvement in overall survival. As such, a review of anti-angiogenic therapy in the treatment of this disease is warranted.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange CA, USA.
authors.forename: Ramez N
authors.initials: RN
authors.lastname: Eskander
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, 101 The City Dr. South, Building 56 Room 264, 101 The City Dr., Orange, CA 92868, USA.
authors.forename: Krishnansu S
authors.initials: KS
authors.lastname: Tewari
keywords: angiogenesis; bevacizumab; cervical cancer